Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.30 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4597407 | 1.00 | CREBBP (0.32) | CREBBPNPSR1HTR2CNPC1LMNA | |
| SCHEMBL4817855 | 0.84 | ALDH1A1 (0.37) | CREBBPHTR2CNPC1TP53RAB9A | |
| SCHEMBL4598285 | 0.84 | ALDH1A1 (0.37) | CREBBPHTR2CNPC1TP53RAB9A | |
| SCHEMBL4555945 | 0.75 | CREBBP (0.36) | CREBBPNPSR1HTR2CLMNAPBRM1 | |
| SCHEMBL4555685 | 0.75 | CREBBP (0.36) | CREBBPNPSR1HTR2CLMNAPBRM1 | |
| SCHEMBL4810522 | 0.71 | HSD11B1 (0.38) | CREBBPHTR2CNPC1TP53RAB9A | |
| SCHEMBL4815232 | 0.70 | CREBBP (0.37) | CREBBPNPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL4816506 | 0.69 | HPGD (0.33) | LMNASMN1; SMN2 | |
| SCHEMBL4598623 | 0.69 | HPGD (0.33) | LMNASMN1; SMN2 | |
| SCHEMBL4817139 | 0.69 | GAA (0.34) | CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293757-A1 | ABCA1 ELEVATING COMPOUNDS | ABELMAN MATTHEW | 2008-11-27 | — | — | US | disclosed |
| US-7432276-B2 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7423045-B2 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| EP-1907395-A1 | ABCA1 ELEVATING COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2008-04-09 | — | — | EP | disclosed |
| US-20070191379-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070010544-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-01-11 | — | — | US | disclosed |
| WO-2007002867-A1 | ABCA1 ELEVATING COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191379-A1 | ABCA1 elevating compounds | ABCD3, ABCB4, CETP | CREBBP 247/4885NPSR1 2921/4885HTR2C 3634/4885 |
| US-20080293757-A1 | ABCA1 ELEVATING COMPOUNDS | ABCD3, ABCB4, CETP | CREBBP 247/4885NPSR1 2921/4885HTR2C 3634/4885 |
| US-20070010544-A1 | ABCA1 elevating compounds | ABCD3, ABCB4, CETP | CREBBP 247/4885NPSR1 2921/4885HTR2C 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.